MX351945B - Mutantes c-raf que confieren resistencia a inhibidores raf. - Google Patents

Mutantes c-raf que confieren resistencia a inhibidores raf.

Info

Publication number
MX351945B
MX351945B MX2014011686A MX2014011686A MX351945B MX 351945 B MX351945 B MX 351945B MX 2014011686 A MX2014011686 A MX 2014011686A MX 2014011686 A MX2014011686 A MX 2014011686A MX 351945 B MX351945 B MX 351945B
Authority
MX
Mexico
Prior art keywords
raf
mutants
inhibitors
confirm resistance
confirm
Prior art date
Application number
MX2014011686A
Other languages
English (en)
Spanish (es)
Other versions
MX2014011686A (es
Inventor
A Garraway Levi
Emery Caroline
Antony Rajee
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Publication of MX2014011686A publication Critical patent/MX2014011686A/es
Publication of MX351945B publication Critical patent/MX351945B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2014011686A 2012-03-28 2013-03-07 Mutantes c-raf que confieren resistencia a inhibidores raf. MX351945B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261616999P 2012-03-28 2012-03-28
US201261708372P 2012-10-01 2012-10-01
PCT/US2013/029513 WO2013148100A1 (en) 2012-03-28 2013-03-07 C-raf mutants that confer resistance to raf inhibitors

Publications (2)

Publication Number Publication Date
MX2014011686A MX2014011686A (es) 2015-06-04
MX351945B true MX351945B (es) 2017-11-03

Family

ID=47892065

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014011686A MX351945B (es) 2012-03-28 2013-03-07 Mutantes c-raf que confieren resistencia a inhibidores raf.

Country Status (15)

Country Link
US (6) US9629839B2 (https=)
EP (3) EP3333575B1 (https=)
JP (3) JP6348898B2 (https=)
KR (1) KR20140139510A (https=)
CN (1) CN104204806B (https=)
AU (1) AU2013240483B2 (https=)
BR (1) BR112014023496A2 (https=)
CA (1) CA2864169A1 (https=)
EA (1) EA028135B1 (https=)
ES (3) ES2673070T3 (https=)
MX (1) MX351945B (https=)
PL (1) PL2831589T3 (https=)
PT (1) PT2831589T (https=)
TR (1) TR201808010T4 (https=)
WO (1) WO2013148100A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3333575B1 (en) * 2012-03-28 2020-02-26 Dana Farber Cancer Institute, Inc. C-raf mutants that confer resistance to raf inhibitors
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
KR102537840B1 (ko) 2018-07-13 2023-05-31 삼성전자 주식회사 서버 장치 및 다른 장치들의 위치 정보를 수집하는 방법
WO2020163771A1 (en) * 2019-02-08 2020-08-13 Portage Glasgow Limited Structure, manufacturing and uses of hoxd12-pde8a cell-penetrating peptides
WO2021225980A1 (en) * 2020-05-04 2021-11-11 Dna-Seq, Inc. Methods and systems for determination of an effective therapeutic regimen and drug discovery

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618670A (en) * 1988-08-26 1997-04-08 The United States Of America As Represented By The Department Of Health & Human Services Detection method for c-raf-1 genes
US20060234931A1 (en) 2003-07-17 2006-10-19 Biggs William H Iii Treatment of diseases with kinase inhibitors
WO2005012875A2 (en) 2003-07-29 2005-02-10 Bristol-Myers Squibb Company Biomarkers of cyclin-dependent kinase modulation
AU2007299080B2 (en) 2006-09-18 2013-04-18 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
CN101516376A (zh) 2006-09-18 2009-08-26 贝林格尔.英格海姆国际有限公司 用于治疗携带egfr突变的癌症的方法
EP2102362B1 (en) * 2006-11-16 2012-07-04 Mount Sinai School of Medicine of New York University Compositions and methods for detecting noonan syndrome
WO2010068738A1 (en) 2008-12-10 2010-06-17 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
BR112012022801B8 (pt) * 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
EP3333575B1 (en) * 2012-03-28 2020-02-26 Dana Farber Cancer Institute, Inc. C-raf mutants that confer resistance to raf inhibitors

Also Published As

Publication number Publication date
US12146196B2 (en) 2024-11-19
AU2013240483B2 (en) 2018-07-26
US20210388325A1 (en) 2021-12-16
US20170204383A1 (en) 2017-07-20
US20240093310A1 (en) 2024-03-21
KR20140139510A (ko) 2014-12-05
EP2831589A1 (en) 2015-02-04
CN104204806B (zh) 2016-02-03
JP6348898B2 (ja) 2018-06-27
US20190142830A1 (en) 2019-05-16
US9629839B2 (en) 2017-04-25
EP3333575A1 (en) 2018-06-13
EA201491780A1 (ru) 2015-01-30
US11788151B2 (en) 2023-10-17
BR112014023496A2 (pt) 2017-07-18
ES2673070T3 (es) 2018-06-19
EP3693741B1 (en) 2022-01-05
CA2864169A1 (en) 2013-10-03
TR201808010T4 (tr) 2018-06-21
JP6661685B2 (ja) 2020-03-11
AU2013240483A1 (en) 2014-08-28
PT2831589T (pt) 2018-06-20
WO2013148100A1 (en) 2013-10-03
JP2020103291A (ja) 2020-07-09
EP3333575B1 (en) 2020-02-26
CN104204806A (zh) 2014-12-10
EP3693741A1 (en) 2020-08-12
JP2015513901A (ja) 2015-05-18
MX2014011686A (es) 2015-06-04
EA028135B1 (ru) 2017-10-31
ES2908078T3 (es) 2022-04-27
US20150133478A1 (en) 2015-05-14
US20250034652A1 (en) 2025-01-30
ES2790896T3 (es) 2020-10-29
PL2831589T3 (pl) 2018-10-31
EP2831589B1 (en) 2018-04-18
JP2018110594A (ja) 2018-07-19

Similar Documents

Publication Publication Date Title
IL284173A (en) Methods of conditioning patients for t cell therapy
CY1124307T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρησεις αυτων
ZA202208792B (en) Methods of treating and preventing graft versus host disease
MX342966B (es) Una mutacion mek1 que confiere resistencia a inhibidores raf y mek.
EA201792642A1 (ru) Способы диагностики для т-клеточной терапии
TW201613962A (en) Fabs-in-tandem immunoglobulin and uses thereof
CL2019001214A1 (es) Composición farmacéutica, métodos para tratamiento y sus usos.
EP3131931A4 (en) Methods for increasing red blood cell levels and treating sickle-cell disease
ECSP13012462A (es) Inmunoglobulinas con dominio variable dual
IL259711A (en) Methods for the preparation of protein kinase inhibitors and their medical use
MX385872B (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
CO6670524A2 (es) Proteínas de unión de dominio variable dual que se unen a ngf y al menos a un blanco adicional, y métodos para hacer y usar dichas proteínas de unión
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
MX2015013166A (es) Proteinas de union especificas duales dirigidas contra il-1 beta y/o il-17.
CL2015002807A1 (es) Terapia de combinación
HUE051632T2 (hu) Betegségek kezelésére szolgáló készítmények és eljárások
UA117556C2 (uk) Спосіб збільшення ефективності терапевтичного засобу шляхом введення метотрексату
WO2012166626A8 (en) Reagents and methods for treating dental disease
IL266636B (en) Biologically stable cannabinoids and a method for increasing their physiological concentration
EA201691314A1 (ru) Терапевтические способы и композиции
BR112014027905A2 (pt) anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
BR112015010220A2 (pt) métodos de utilização de biomarcadores para tratamento de câncer
MX386374B (es) Composiciones farmacéuticas y alimenticias para inducir la saciedad y prolongar la saciedad en sujetos que lo necesiten.
WO2013055418A3 (en) Cross-protective arenavirus vaccines and their method of use
MX351945B (es) Mutantes c-raf que confieren resistencia a inhibidores raf.

Legal Events

Date Code Title Description
FG Grant or registration